ALT and AST levels were also unaffected although GGT levels were reduced; this suggests the potential for a liver benefit given that GGT levels are frequently elevated (and may confer a higher risk of progression) in the context of NAFLD.56 This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.